Teva/Ivax closing date extended
Executive Summary
The closing date for Teva's acquisition of Ivax has been extended, Teva announces Jan. 10; the consent order for the acquisition is still under review by the Federal Trade Commission, company reports. The two generics firms "have no reason to believe that the acceptance will not be forthcoming shortly, and expect to close the merger later this month." Teva announced the $7.4 bil. acquisition in July 2005 (1"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.